Business Context and Reporting Period
This Form 6-K filing by Meiwu Technology Company Limited, dated January 7, 2025, reports significant changes to the Company's Board of Directors and executive leadership effective December 27, 2024, and January 6, 2025. The Company is a British Virgin Islands entity operating in the healthcare and functional skincare sectors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and executive appointments rather than financial performance.
Material Changes
Departures of Officers and Directors
- Mr. Xinliang Zhang: Resigned as Co-Chief Executive Officer (Co-CEO) and Director effective December 27, 2024, for personal reasons.
- Ms. Jinfeng He: Resigned as Director and member of the Audit, Nominating, and Compensation Committees effective December 27, 2024, for personal reasons.
- Mr. Lam Kit Lam: Resigned as Director, Chairman of the Compensation Committee, and member of the Audit and Nominating Committees effective December 27, 2024, for personal reasons.
- Ms. Xiaoying Mu: Resigned as Director, Chairwoman of the Audit and Nominating Committees, and member of the Compensation Committee effective December 27, 2024, for personal reasons.
- Ms. Qiulan Li: Ceased serving as Co-CEO upon the appointment of Mr. Zhichao Yang but remains a Director.
The Company stated that none of these resignations resulted from disagreements regarding operations, policies, or practices.
Appointments of Officers and Directors
- Mr. Zhichao Yang: Appointed Chief Executive Officer (CEO) and Director effective January 6, 2025. He brings extensive experience in healthcare and functional skincare operations. His annual base salary is set at $200,000.
- Mr. Peiqun Lin: Appointed Director effective January 6, 2025. He will serve as Chairman of the Audit Committee and is experienced in marketing and brand development.
- Mr. Aiwei Luo: Appointed Director effective January 6, 2025. He will serve as Chairman of the Compensation Committee and has a background in financial management.
- Mr. Hanwu Yang: Appointed Director effective January 6, 2025. He has experience in marketing and previously served as Marketing Director for a Company-controlled variable interest entity.
Committee Restructuring
Following the departures, the Board reconstituted its committees with the newly appointed independent directors:
- Audit Committee: Mr. Aiwei Luo, Mr. Peiqun Lin (Chairman), and Ms. Qiufei Chen.
- Nominating Committee: Mr. Aiwei Luo, Mr. Peiqun Lin, and Ms. Qiufei Chen (Chairwoman).
- Compensation Committee: Mr. Aiwei Luo (Chairman), Mr. Peiqun Lin, and Ms. Qiufei Chen.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors beyond the standard disclosure that the resignations were not due to disagreements. The appointment of a new CEO with a background in healthcare and skincare suggests a continued strategic focus on these sectors.
Investor Verification Checklist
- Verify the transition plan and operational continuity following the resignation of the Co-CEO and multiple board members.
- Review the employment agreement and offer letters (Exhibits 10.1 through 10.5) for details on Mr. Yang's compensation and the terms of the new directors.
- Confirm the independence status of the new committee members under NASDAQ Capital Market rules.
- Monitor future filings for the first financial results under the new leadership structure.